3 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 112 points (0.7%) at 16,695 as of Monday, May 12, 2014, 4:20 PM ET. The NYSE advances/declines ratio sits at 2,429 issues advancing vs. 632 declining with 133 unchanged.

The Drugs industry as a whole closed the day up 2.1% versus the S&P 500, which was up 1.0%. Top gainers within the Drugs industry included Natural Alternatives International ( NAII), up 2.2%, XTL Biopharmaceuticals ( XTLB), up 4.9%, Reliv' International ( RELV), up 6.7%, EntreMed ( ENMD), up 2.4% and ProPhase Labs ( PRPH), up 4.6%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

EntreMed ( ENMD) is one of the companies that pushed the Drugs industry higher today. EntreMed was up $0.04 (2.4%) to $1.80 on light volume. Throughout the day, 8,596 shares of EntreMed exchanged hands as compared to its average daily volume of 22,100 shares. The stock ranged in a price between $1.71-$1.80 after having opened the day at $1.74 as compared to the previous trading day's close of $1.75.

EntreMed has a market cap of $48.4 million and is part of the health care sector. Shares are up 5.0% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on ENMD go as follows:

You can view the full analysis from the report here: EntreMed Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Reliv' International ( RELV) was up $0.13 (6.7%) to $2.06 on light volume. Throughout the day, 6,592 shares of Reliv' International exchanged hands as compared to its average daily volume of 15,400 shares. The stock ranged in a price between $1.91-$2.08 after having opened the day at $1.91 as compared to the previous trading day's close of $1.93.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $25.6 million and is part of the health care sector. Shares are down 31.3% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Reliv' International a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • RELV's debt-to-equity ratio is very low at 0.23 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.82 is somewhat weak and could be cause for future problems.
  • The gross profit margin for RELIV INTERNATIONAL INC is currently very high, coming in at 80.04%. Regardless of RELV's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of -1.04% trails the industry average.
  • RELV, with its decline in revenue, underperformed when compared the industry average of 0.1%. Since the same quarter one year prior, revenues fell by 23.3%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Personal Products industry. The net income has significantly decreased by 177.4% when compared to the same quarter one year ago, falling from $0.20 million to -$0.15 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Personal Products industry and the overall market, RELIV INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

XTL Biopharmaceuticals ( XTLB) was another company that pushed the Drugs industry higher today. XTL Biopharmaceuticals was up $0.14 (4.9%) to $3.05 on light volume. Throughout the day, 2,000 shares of XTL Biopharmaceuticals exchanged hands as compared to its average daily volume of 9,100 shares. The stock ranged in a price between $3.01-$3.16 after having opened the day at $3.16 as compared to the previous trading day's close of $2.91.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. XTL Biopharmaceuticals has a market cap of $39.3 million and is part of the health care sector. Shares are up 0.3% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate XTL Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates XTL Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on XTLB go as follows:

  • XTL BIOPHARMACEUTICALS has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, XTL BIOPHARMACEUTICALS reported poor results of -$0.22 versus -$0.13 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 288.5% when compared to the same quarter one year ago, falling from -$0.30 million to -$1.15 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, XTL BIOPHARMACEUTICALS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 44.53%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 233.33% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • Net operating cash flow has decreased to -$0.52 million or 27.45% when compared to the same quarter last year. Despite a decrease in cash flow of 27.45%, XTL BIOPHARMACEUTICALS is in line with the industry average cash flow growth rate of -30.98%.

You can view the full analysis from the report here: XTL Biopharmaceuticals Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Dow Trades Higher, Nasdaq Slides as Chipmakers Fall

Dow Trades Higher, Nasdaq Slides as Chipmakers Fall

What Is Vertical Integration and What Are The Benefits?

What Is Vertical Integration and What Are The Benefits?

11 Investing Lessons Jim Cramer Has Learned This Year

11 Investing Lessons Jim Cramer Has Learned This Year

Stocks Destined for a Plunge so Don't Let Thursday's Epic Dow Rally Fool You

Stocks Destined for a Plunge so Don't Let Thursday's Epic Dow Rally Fool You

Elon Musk Tells New York Times Tweet Was Attempt at Transparency

Elon Musk Tells New York Times Tweet Was Attempt at Transparency